| 新冠病毒中和单克隆抗体及纳米抗体研究进展北大核心CSCD |
| |
| 引用本文： | 陈玉磊,林锦锦,郑培义,曹敏杰,金腾川.新冠病毒中和单克隆抗体及纳米抗体研究进展北大核心CSCD[J].生物工程学报,2022,38(9):3173-3193. |
| |
| 作者姓名： | 陈玉磊 林锦锦 郑培义 曹敏杰 金腾川 |
| |
| 作者单位： | 集美大学 海洋食品与生物工程学院, 福建 厦门 361021;中国科学技术大学 基础医学院, 安徽 合肥 230027 |
| |
| 基金项目： | 中国科学院战略先导项目（XDB29030104）；福建省自然科学基金（2021J01838）；国家自然科学基金（31870731,31772049）；国家重点研发计划（2018YFD0901004） |
| |
| 摘 要： | 由严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus-2,SARS-CoV-2)引起的疾病被命名为新型冠状病毒肺炎(coronavirus disease 2019,COVID-19),是一种具有强传染性、高易感性、长潜伏期的传染病。病毒刺突蛋白受体结合结构域(receptor binding domain,RBD)和细胞血管紧张素转换酶2(angiotensin-converting enzyme 2,ACE2)之间的相互作用使得SARS-CoV-2顺利进入细胞。本文对SARS-CoV-2与ACE2的相关作用机制进行了简单概述,对目前针对SARS-CoV-2中和单克隆抗体、纳米抗体的最新研究进展进行了总结,探讨了新冠肺炎的发展过程和抗体药物的研究方向,以期为包括新冠肺炎在内的新发、突发传染病中和抗体药物的研发提供参考。
|
| 关 键 词： | 新冠病毒 新型冠状病毒肺炎 受体结合结构域 单克隆抗体 纳米抗体 |
| 收稿时间： | 2022/4/21 0:00:00 |
SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies:a review |
| |
| CHEN Yulei,LIN Jinjin,ZHENG Peiyi,CAO Minjie,JIN Tengchuan.SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies:a review[J].Chinese Journal of Biotechnology,2022,38(9):3173-3193. |
| |
| Authors: | CHEN Yulei LIN Jinjin ZHENG Peiyi CAO Minjie JIN Tengchuan |
| |
| Institution: | College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China;School of Basic Medical Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China |
| |
| Abstract: | Coronavirus disease (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with strong contagiousness, high susceptibility and long incubation period. cell entry by SARS-CoV-2 requires the binding between the receptor-binding domain of the viral spike protein and the cellular angiotensin-converting enzyme 2 (ACE2). Here, we briefly reviewed the mechanisms underlying the interaction between SARS-CoV-2 and ACE2, and summarized the latest research progress on SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies, so as to better understand the development process and drug research direction of COVID-19. This review may facilitate understanding the development of neutralizing antibody drugs for emerging infectious diseases, especially for COVID-19. |
| |
| Keywords: | SARS-CoV-2 COVID-19 receptor binding domain monoclonal antibody nanobody |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《生物工程学报》浏览原始摘要信息 |
| 点击此处可从《生物工程学报》下载免费的PDF全文 |
|
